Stocktoria
Processa Pharmaceuticals, Inc. PCSA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-10-07
Processa Pharmaceuticals, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 |
| R&D expense | — | — | $5.8M | $11.5M | $6.9M |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$27.5M | -$12.1M |
| Interest expense | — | — | — | — | $362 |
| Income tax | — | — | — | — | -$530,611 |
| Net income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$11.4M |
| EPS (diluted) | $-10.36 | $-96.78 | $-8.48 | $-34.05 | — |
| Operating cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M | -$8.7M |
| Free cash flow | — | -$11.2M | -$8.1M | — | — |
| Cash & equivalents | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M |
| Total liabilities | $2.2M | $1.5M | $797,484 | $1.1M | $978,405 |
| Shareholders' equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M |
Source: SEC EDGAR filings · CIK 0001533743 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.